Phloretin promotes osteoclast apoptosis in murine macrophages and inhibits estrogen deficiency-induced osteoporosis in mice

Phytomedicine

Volumn 21, Issue 10, 2014, Pages 1208-1215

  Lee, Eun Jung ^a   Kim, Jung Lye ^a   Kim, Yun Ho ^a   Kang, Min Kyung ^a   Gong, Ju Hyun ^a   Kang, Young Hee ^a  

^a Hallym University   (South Korea)

Author keywords

Estrogen deficiency; Osteoclast apoptosis; Osteoporosis; Ovariectomy; Phloretin

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; APOPTOSIS SIGNAL REGULATING KINASE 1; BETA3 INTEGRIN; CARBONATE DEHYDRATASE II; CASPASE 3; ESTRADIOL; MITOGEN ACTIVATED PROTEIN KINASE P38; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PHLORETIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN C JUN; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; ESTROGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; APPLE; ARTICLE; BONE DENSITY; C57BL 6 MOUSE; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ESTROGEN DEFICIENCY; FEMALE; FEMUR; GENETIC TRANSCRIPTION; MACROPHAGE; MEDICINAL PLANT; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; OVARIECTOMY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UTERUS; ADVERSE EFFECTS; ANIMAL; BIOLOGICAL MODEL; C57BL MOUSE; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; HUMAN; OSTEOPOROSIS, POSTMENOPAUSAL; PATHOPHYSIOLOGY; TUMOR CELL LINE;

MALUS X DOMESTICA; MURINAE; MUS;

ANIMALS; APOPTOSIS; BONE RESORPTION; CELL DIFFERENTIATION; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; ESTROGENS; FEMALE; HUMANS; MACROPHAGES; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED C57BL; MODELS, BIOLOGICAL; OSTEOCLASTS; OSTEOPOROSIS, POSTMENOPAUSAL; OVARIECTOMY; PHLORETIN;

EID: 84905013658     PISSN: 09447113     EISSN: 1618095X     Source Type: Journal    
DOI: 10.1016/j.phymed.2014.04.002     Document Type: Article

References (32)

1. K. Akesson New approaches to pharmacological treatment of osteoporosis Bull. World Health Organ. 81 2003 657 664
2. A.F. Al-Anazi, V.F. Qureshi, K. Javaid, and S. Qureshi Preventive effects of phytoestrogens against postmenopausal osteoporosis as compared to the available therapeutic choices: an overview J. Nat. Sci. Biol. Med. 2 2011 154 163
3. J. Banu, E. Varela, and G. Fernandes Alternative therapies for the prevention and treatment of osteoporosis Nutr. Rev. 70 2012 22 40
4. M.K. Beard Bisphosphonate therapy for osteoporosis: combining optimal fracture risk reduction with patient preference Curr. Med. Res. Opin. 28 2012 141 147
5. S. Bedell, M. Nachtigall, and F. Naftolin The pros and cons of plant estrogens for menopause J. Steroid Biochem. Mol. Biol. 139 2014 225 236
6. H.C. Blair, and M. Zaidi Osteoclastic differentiation and function regulated by old and new pathways Rev. Endocr. Metab. Disord. 7 2006 23 32
7. M. Cicek, A. Vrabel, C. Sturchio, L. Pederson, J.R. Hawse, M. Subramaniam, T.C. Spelsberg, and M.J. Oursler TGF-β inducible early gene 1 regulates osteoclast differentiation and survival by mediating the NFATc1, AKT, and MEK/ERK signaling pathways PLoS ONE 6 2011 e17522
8. B. Dawson-Hughes, and H.A. Bischoff-Ferrari Therapy of osteoporosis with calcium and vitamin D J. Bone Miner. Res. 22 Suppl. 2 2007 V59L V63
9. L.J. Dominguez, G. Di Bella, M. Belvedere, and M. Barbagallo Physiology of the aging bone and mechanisms of action of bisphosphonates Biogerontology 12 2011 397 408
10. E.F. Eriksen Cellular mechanisms of bone remodeling Rev. Endocr. Metab. Disord. 11 2010 219 227
11. E.F. Eriksen Hormone replacement therapy or SERMS in the long term treatment of osteoporosis Minerva Ginecol. 64 2012 207 221
12. L.A. Fraser, K.N. Vogt, J.D. Adachi, and L. Thabane Fracture risk associated with continuation versus discontinuation of bisphosphonates after 5 years of therapy in patients with primary osteoporosis: a systematic review and meta-analysis Therapeut. Clin. Risk Manage. 7 2011 157 166
13. K. Hagiwara, T. Goto, M. Araki, H. Miyazaki, and H. Hagiwara Olive polyphenol hydroxytyrosol prevents bone loss Eur. J. Pharmacol. 662 2011 78 84
14. K. Henriksen, D.J. Leeming, C. Christiansen, and M.A. Karsdal Use of bone turnover markers in clinical osteoporosis assessment in women: current issues and future options Womens Health 7 2011 689 698
15. I. Idris, and R. Donnelly Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug Diabetes Obes. Metab. 11 2009 79 88
16. R. Josse, A. Khan, D. Ngui, and M. Shapiro Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis Curr. Med. Res. Opin. 29 2013 205 216
17. M. Jung, S. Triebel, T. Anke, E. Richling, and G. Erkel Influence of apple polyphenols on inflammatory gene expression Mol. Nutr. Food Res. 53 2009 1263 1280
18. I. Kaczmarczyk-Sedlak, W. Wojnar, M. Zych, E. Ozimina-Kamińska, J. Taranowicz, and A. Siwek Effect of formononetin on mechanical properties and chemical composition of bones in rats with ovariectomy-induced osteoporosis Evid. Based Complement. Alternat. Med. 2013 457052
19. M. Kamon, R. Zhao, and K. Sakamoto Green tea polyphenol (-)-epigallocatechin gallate suppressed the differentiation of murine osteoblastic MC3T3-E1 cells Cell Biol. Int. 34 2009 109 116
20. J.A. Kanis Diagnosis of osteoporosis and assessment of fracture risk Lancet 359 2002 1929 1936
21. S. Khosla Minireview: the OPG/RANKL/RANK system Endocrinology 142 2001 5050 5055
22. J.L. Kim, M.K. Kang, J.H. Gong, S.H. Park, S.Y. Han, and Y.H. Kang Novel antiosteoclastogenic activity of phloretin antagonizing RANKL-induced osteoclast differentiation of murine macrophages Mol. Nutr. Food. Res. 56 2012 1223 1233
23. P. Proff, and P. Römer The molecular mechanism behind bone remodeling: a review Clin. Oral Investig. 13 2009 355 362
24. L. Rejnmark, and L. Mosekilde New and emerging antiresorptive treatments in osteoporosis Curr. Drug Saf. 6 2011 75 88
25. P. Sunita, and S.P. Pattanayak Phytoestrogens in postmenopausal indications: a theoretical perspective Pharmacogn. Rev. 5 2011 41 47
26. M. Tao, Y. Teng, H. Shao, P. Wu, and E.J. Mills Knowledge, perceptions and information about hormone therapy (HT) among menopausal women: a systematic review and meta-synthesis PLoS ONE 6 2011 e24661
27. J.V. Turner, S. Agatonovic-Kustrin, and B.D. Glass Molecular aspects of phytoestrogen selective binding at estrogen receptors J. Pharm. Sci. 96 2007 1879 1885
28. L. Xing, E.M. Schwarz, and B.F. Boyce Osteoclast precursors, RANKL/RANK, and immunology Immunol. Rev. 208 2005 19 29
29. T. Wada, T. Nakashima, N. Hiroshi, and J.M. Penninger RANKL-RANK signaling in osteoclastogenesis and bone disease Trends Mol. Med. 12 2006 17 25
30. J. Wang, M.H. Chung, B. Xue, H. Ma, C. Ma, and M. Hattori Estrogenic and antiestrogenic activities of phloridzin Biol. Pharm. Bull. 33 2010 592 597
31. Y.C. Yang, C.K. Li, A.H. Lin, Y.W. Yeh, H.T. Yao, C.C. Li, K.L. Liu, and H.W. Chen Induction of glutathione synthesis and heme oxygenase 1 by the flavonoids butein and phloretin is mediated through the ERK/Nrf2 pathway and protects against oxidative stress Free Radic. Biol. Med. 51 2011 2073 2081
32. D.W. Zhang, Y. Cheng, N.L. Wang, J.C. Zhang, M.S. Yang, and X.S. Yao Effects of total flavonoids and flavonol glycosides from Epimedium koreanum Nakai on the proliferation and differentiation of primary osteoblasts Phytomedicine 15 2008 55 61